Investigational drug · Phase 3
KPS-0373
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinocerebellar Degeneration.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "KPS-0373"
First trial start
2025
Aug 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KPS-0373", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinocerebellar Degeneration
Largest trials
Live from ClinicalTrials.gov: studies naming "KPS-0373" as an intervention, largest first.
- A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01970098 · 374 participants · Start Oct 9, 2013 · Primary completion Jan 2015
Drug: KPS-0373, High dose; KPS-0373, Low dose and 1 more · For: Spinocerebellar Degeneration
Sites: Multiple Locations, Japan
- An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT02889302 · 203 participants · Start Nov 15, 2016 · Primary completion Mar 2018
Drug: KPS-0373; Placebo · For: Spinocerebellar Degeneration
Sites: Multiple Locations, Japan
- A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01384435 · 200 participants (planned)
Drug: KPS-0373; KPS-0373 and 3 more · For: SCD
Sites: Tokyo and Other Japanese City, Japan
- Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar DegenerationPivotal-lookingActive, not recruiting
Kissei Pharmaceutical Co., Ltd.Industry
NCT07040137 · 142 participants (planned) · Start Aug 15, 2025 · Primary completion Mar 31, 2027
Drug: KPS-0373; Placebo · For: Spinocerebellar Degeneration
Sites: Tokyo and Other Japanese Cities, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT00863538 · 40 participants (planned)
Drug: KPS-0373 · For: Spinocerebellar Degeneration
Sites: Hokkaido Region, Japan; Kansai Region, Japan; Kanto Region, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT01004016 · 20 participants (planned)
Drug: KPS-0373; Placebo · For: Spinocerebellar Degeneration
Sites: Japan, Japan
- An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01970111 · Primary completion Jul 2015
Drug: KPS-0373, High dose; KPS-0373, Low dose · For: Spinocerebellar Degeneration
Sites: Tokyo and Other Japanese Cities, Japan
- A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01970137 · Primary completion Oct 2014
Drug: KPS-0373, High dose; KPS-0373, Low dose · For: Spinocerebellar Degeneration
Sites: Tokyo and Other Japanese Cities, Japan
- A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Pivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT01970124 · Primary completion May 2015
Drug: KPS-0373, High dose; KPS-0373, Low dose · For: Spinocerebellar Degeneration
Sites: Tokyo and Other Japanese Cities, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.